Lv4
680 积分 2021-03-22 加入
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
5小时前
已完结
The next generation of immunotherapies for lung cancers
25天前
已完结
Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients with Resectable NSCLC: Still an Open Question. Comments on Marinelli et al. J Thorac Oncol. 2025;20:285–295
1个月前
已关闭
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1个月前
已完结
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
2个月前
已完结
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity
3个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
3个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
3个月前
已完结
Analysis of China-to-West pharmaceutical licensing deals in 2024
3个月前
已关闭
皖公网安备34019202002308
